Quince Therapeutics, Inc. Retained Earnings
Quince Therapeutics, Inc. (QNCX) had Retained Earnings of -$500.03 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-14
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$500.03M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$424.54M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$460.45M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$420.99M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$500.03M 10-Q · filed 2026-08-14 |
| 2026-03-31 | -$424.54M 10-Q · filed 2026-05-11 |
| 2025-12-31 | -$460.45M 10-Q · filed 2026-08-14 |
| 2025-09-30 | -$420.99M 10-Q · filed 2025-11-12 |
| 2025-06-30 | -$407.55M 10-Q · filed 2025-08-11 |
| 2025-03-31 | -$391.50M 10-Q · filed 2025-05-13 |
| 2024-12-31 | -$376.47M 10-K · filed 2026-04-10 |
| 2024-09-30 | -$364.01M 10-Q · filed 2024-11-13 |
| 2024-06-30 | -$358.52M 10-Q · filed 2024-08-13 |
| 2024-03-31 | -$330.79M 10-Q · filed 2024-05-13 |
| 2023-12-31 | -$319.64M 10-K · filed 2025-03-24 |
| 2023-09-30 | -$310.75M 10-Q · filed 2023-11-14 |
| 2023-06-30 | -$305.40M 10-Q · filed 2023-08-03 |
| 2023-03-31 | -$300.51M 10-Q · filed 2023-05-15 |
| 2022-12-31 | -$288.26M 10-K · filed 2024-04-01 |
| 2022-09-30 | -$282.73M 10-Q · filed 2022-11-09 |
| 2022-06-30 | -$274.80M 10-Q · filed 2022-08-09 |
| 2022-03-31 | -$258.24M 10-Q · filed 2022-05-10 |
| 2021-12-31 | -$236.60M 10-K · filed 2023-03-15 |
| 2021-09-30 | -$213.20M 10-Q · filed 2021-10-29 |
| 2021-06-30 | -$191.49M 10-Q · filed 2021-08-06 |
| 2021-03-31 | -$169.74M 10-Q · filed 2021-05-06 |
| 2020-12-31 | -$146.65M 10-K · filed 2022-03-01 |
| 2020-09-30 | -$126.10M 10-Q · filed 2020-11-12 |
| 2020-06-30 | -$104.59M 10-Q · filed 2020-08-14 |
| 2020-03-31 | -$86.98M 10-Q · filed 2020-05-12 |
| 2019-12-31 | -$69.81M 10-K · filed 2021-03-01 |
| 2019-09-30 | -$57.43M 10-Q · filed 2019-11-12 |
| 2019-06-30 | -$47.57M 10-Q · filed 2019-08-09 |
| 2019-03-31 | -$38.51M 10-Q · filed 2019-06-12 |
| 2018-12-31 | -$32.83M 10-K · filed 2020-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |